Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The chromatid lesion at the site of EBV integration involving a recombinogenic and fragile site may have contributed to the development of the NAB-2 BL.
|
8391183 |
1993 |
Adult Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The chromatid lesion at the site of EBV integration involving a recombinogenic and fragile site may have contributed to the development of the NAB-2 BL.
|
8391183 |
1993 |
Childhood Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The chromatid lesion at the site of EBV integration involving a recombinogenic and fragile site may have contributed to the development of the NAB-2 BL.
|
8391183 |
1993 |
liposarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The human NAB2 gene has been localized to chromosome 12ql3.3-14.1, a region that is rearranged in several solid tumors, lipomas, uterine leiomyomata, and liposarcomas.
|
8668170 |
1996 |
Malignant neoplasm of prostate
|
0.120 |
AlteredExpression
|
disease |
BEFREE |
Our findings suggest that high levels of EGR1 coupled with low levels of NAB2 can result in high, unrestrained EGR1 transcriptional activity in human prostate cancers.
|
11567222 |
2001 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, loss of NAB2 did not correlate with the tumor grade or stage.
|
11567222 |
2001 |
Prostate carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We show here that NAB2 protein expression is lost in a majority of primary prostate carcinoma specimens, including many samples that have high EGR1 levels.
|
11567222 |
2001 |
Prostatic Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
The human NAB2 gene has been localized to 12q13.3-14.1, within a chromosomal region that is thought to harbor a prostate tumor suppressor.
|
11567222 |
2001 |
Peripheral Nervous System Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Therefore, our analysis indicates that mutations in the human NABI and NAB2 genes are most likely not involved in the pathogenesis of peripheral neuropathies.
|
12030330 |
2002 |
Congenital hypomyelinating neuropathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Mice lacking both Nab1 and Nab2 show severe congenital hypomyelination of peripheral nerves, with Schwann cell development arresting at the promyelinating stage, despite elevated Egr2 expression.
|
16136673 |
2005 |
Malignant neoplasm of prostate
|
0.120 |
PosttranslationalModification
|
disease |
BEFREE |
NAB2 and CDC6 were hypermethylated frequently in pCA (92%, 67%, respectively) and in BPH (91%, 59%, respectively).
|
16956712 |
2007 |
Prostate carcinoma
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
NAB2 and CDC6 were hypermethylated frequently in pCA (92%, 67%, respectively) and in BPH (91%, 59%, respectively).
|
16956712 |
2007 |
Squamous cell carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Real-time RT-PCR analysis was conducted on a selected subset of these genes (S100A2, GPC4, p72, IGFBP-5, TRIM2 and NAB2) for 14 additional SCCs and 10 normal epithelia.
|
17290407 |
2007 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although weak correlation was found between EGR-1 and NAB-2 expressions on the whole, NAB-2 expression decreased as tumors dedifferentiated, and inhibition of DNA methyltransferase/histone deacetylase increased NAB-2 expression in lung cancer cells despite no epigenetic alteration in the NAB-2 promoter.
|
20489156 |
2010 |
Malignant neoplasm of lung
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
These findings suggest that EGR-1 plays important roles on VEGF-A expression in lung cancer cells, and epigenetic silencing of transactivator(s) associated with NAB-2 expression might also contribute to upregulate VEGF-A expression.
|
20489156 |
2010 |
Carcinoma of lung
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
These findings suggest that EGR-1 plays important roles on VEGF-A expression in lung cancer cells, and epigenetic silencing of transactivator(s) associated with NAB-2 expression might also contribute to upregulate VEGF-A expression.
|
20489156 |
2010 |
Primary malignant neoplasm of lung
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
These findings suggest that EGR-1 plays important roles on VEGF-A expression in lung cancer cells, and epigenetic silencing of transactivator(s) associated with NAB-2 expression might also contribute to upregulate VEGF-A expression.
|
20489156 |
2010 |
Solitary fibrous tumor
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These studies establish NAB2-STAT6 as the defining driver mutation of SFT and provide an example of how neoplasia can be initiated by converting a transcriptional repressor of mitogenic pathways into a transcriptional activator.
|
23313952 |
2013 |
Solitary fibrous tumor
|
0.600 |
FusionGene
|
disease |
ORPHANET |
These studies establish NAB2-STAT6 as the defining driver mutation of SFT and provide an example of how neoplasia can be initiated by converting a transcriptional repressor of mitogenic pathways into a transcriptional activator.
|
23313952 |
2013 |
Solitary fibrous tumor
|
0.600 |
Biomarker
|
disease |
CTD_human |
These studies establish NAB2-STAT6 as the defining driver mutation of SFT and provide an example of how neoplasia can be initiated by converting a transcriptional repressor of mitogenic pathways into a transcriptional activator.
|
23313952 |
2013 |
hemangiopericytoma
|
0.380 |
FusionGene
|
disease |
ORPHANET |
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing.
|
23313952 |
2013 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Transcriptome sequencing of 27 additional SFTs identified the presence of a NAB2-STAT6 gene fusion in all tumors.
|
23313952 |
2013 |
Solitary fibrous tumor
|
0.600 |
Biomarker
|
disease |
BEFREE |
Analysis in 53 tumors confirmed the presence of 7 variants of this fusion transcript in 29 tumors (55%), representing a lower bound for fusion frequency at this locus and suggesting that the NAB2-STAT6 fusion is a distinct molecular feature of SFTs.
|
23313954 |
2013 |
Solitary fibrous tumor
|
0.600 |
FusionGene
|
disease |
ORPHANET |
Analysis in 53 tumors confirmed the presence of 7 variants of this fusion transcript in 29 tumors (55%), representing a lower bound for fusion frequency at this locus and suggesting that the NAB2-STAT6 fusion is a distinct molecular feature of SFTs.
|
23313954 |
2013 |
Solitary fibrous tumor
|
0.600 |
Biomarker
|
disease |
CTD_human |
Analysis in 53 tumors confirmed the presence of 7 variants of this fusion transcript in 29 tumors (55%), representing a lower bound for fusion frequency at this locus and suggesting that the NAB2-STAT6 fusion is a distinct molecular feature of SFTs.
|
23313954 |
2013 |